Canada markets open in 8 hours 2 minutes

Canntab Therapeutics Limited (TBF1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.2020-0.0040 (-1.94%)
At close: 08:02AM CEST
Full screen
Previous Close0.2060
Open0.2020
Bid0.2020 x 0
Ask0.2160 x 0
Day's Range0.2020 - 0.2020
52 Week Range0.1400 - 0.5850
Volume41
Avg. Volume0
Market Cap7.955M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    Canntab Corporate Update

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing a corporate update to its shareholders and stakeholders. Further to the announcement made by Canntab on April 14, 2022 with respect to our exploration of a variety of alternative business strategies including potential M&A opportunities, as well as identifying and negotiating partnership

  • CNW Group

    CANNTAB ANNOUNCES CHANGE OF AUDITOR

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces that that it has changed its auditor from MNP LLP (the "Former Auditor") to Clearhouse LLP (the "Successor Auditor"). The Former Auditor resigned effective May 27, 2022, at the Company's request, and the Company's board of directors appointed the Successor Auditor to fill the resulting vaca

  • CNW Group

    Canntab Engages Hamish Sutherland as Strategic Advisor

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that the Company has engaged Mr. Hamish Sutherland as a strategic business consultant to work with Canntab and develop additional sales and distribution channels for the extensive suite of Canntab's products and to assist Canntab in reaching strategic partnerships in the Cannab